Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric
B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease. 1
Cycle of blinatumomab treatment followed by hematopoietic stem cell transplantation.
Blinatumomab has approved to treat adults and children with B-cell precursor ALL who are in
remission but still have MRD. However, data on the effects and safety of blinatumomab in
children with B-precursor ALL with MRD positive are insufficient.